Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Cognitive Test Battery 1, Cognitive Test Battery 2 · 1 trial · 1 indication
The cognitive data will be summarized and summary statistics calculated (including mean, standard deviation, median, minimum, and maximum values) for each experiment and participants group.
| Arm | Type | Description |
|---|---|---|
| Group 1: Patients with schizophrenia | EXPERIMENTAL | - |
| Group 2: Young healthy volunteers | ACTIVE_COMPARATOR | - |
| Group 3: Elderly healthy volunteers | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| Cognitive Test Battery 1 | BEHAVIORAL | The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT\_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT\_Expl); Delayed Recall and Recognition Test; and Pursuit rotor. |
| Cognitive Test Battery 2 | BEHAVIORAL | The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task. |
Inclusion Criteria: * Group 1 (patients with schizophrenia): * Be a man or woman between 18 and 55 years of age, inclusive * Has a known history of schizophrenia of at least 12 months by the referring psychiatrist * Receives stable antipsychotic drug therapy (maximally 2) for at least 6 weeks prior...
Cognitive Test Battery 1 and Cognitive Test Battery 2 are investigational cognitive test batteries being studied for use in schizophrenia. They are intended to assess learning performance in patients with schizophrenia, as well as in young and elderly healthy volunteers, according to a completed early Phase 1 clinical trial.
Johnson & Johnson (NYSE: JNJ) is the developer of Cognitive Test Battery 1 and Cognitive Test Battery 2. The company sponsored a clinical study of these test batteries in schizophrenia, which was conducted in Belgium.
Cognitive Test Battery 1 and Cognitive Test Battery 2 are in early Phase 1 clinical development. A study of these test batteries, identified as NCT01788436, was completed with 51 participants. They remain investigational and are not approved for clinical use.
Cognitive Test Battery 1 and Cognitive Test Battery 2 were evaluated in one completed clinical trial, NCT01788436, titled 'A Study to Assess Learning Performance in Patients With Schizophrenia and Young and Elderly Healthy Volunteers.' The study enrolled 51 participants in Belgium and included healthy volunteers.
Cognitive Test Battery 1 and Cognitive Test Battery 2 are two distinct test batteries developed by Johnson & Johnson. They were both evaluated in the same clinical trial, NCT01788436, which assessed learning performance in schizophrenia patients and healthy volunteers, but they are separate instruments.